Showing 8381-8390 of 9737 results for "".
- Provectus Receives Patent for Investigational Melanoma Agent PV-10https://practicaldermatology.com/news/provectus-receives-patient-for-investigational-melanoma-agent-pv-10/2458891/Provectus Biopharmaceuticals, Inc. has received a patent from the US Patent and Trademark Office, protecting the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination wit
- Nuvo Research Granted US Patent for Topical Onychomycosis Formulationhttps://practicaldermatology.com/news/nuvo-research-granted-us-patent-for-topical-onychomycosis-formulation/2458896/The United States Patent and Trademark Office granted a new U.S. patent number 9,084,754 ('754 Patent) to Nuvo Research Inc. for its highly permeating topical formulations of terbinafine, an antifungal drug, and methods for treating onychomycosis. The '754 Patent will expire on March 8, 2
- Court Rules in Favor of Amarin Corp. in "Off-label" Disputehttps://practicaldermatology.com/news/court-rules-in-favor-of-amarin-corp-in-off-label-dispute/2458897/Amarin Corporation plc (NASDAQ: AMRN) today announced a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin'slead product, Vascepa®(icosapent ethyl) c
- Cellfina Cleared to Treat Cellulite for Up to Two Yearshttps://practicaldermatology.com/news/cellfina-cleared-to-treat-cellulite-for-up-to-two-years/2458898/The Cellfina System from Ulthera, Inc. has received FDA clearance for the long-term improvement in the appearance of cellulite on the buttocks and thighs with no loss of benefit for up to 2 years. Ulthera is a a wholly-owned subsidiary of Merz, Inc. The
- Finacea Foam 15% Approved for Treatment of Inflammatory Papules and Pustules in Patients with Mild to Moderate Rosaceahttps://practicaldermatology.com/news/finacea-foam-15-approved-for-treatment-of-inflammatory-papules-and-pustules-in-patients-with-mild-to-moderate-rosacea/2458899/The FDA approved Finacea® (azelaic acid) Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The approval is based on results from two pivotal clinical trials examining the efficacy and safety of Finacea® Foam com
- FDA Approves Odomzo for Locally Advanced BCChttps://practicaldermatology.com/news/fda-approves-odomzo-sonidegib-for-locally-advanced-bcc/2458903/The FDA approved Novartis’ Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radi
- Novartis Combination Therapy Tafinlar and Mekinist Receives FDA Priority Review Designationhttps://practicaldermatology.com/news/novartis-combination-therapy-tafinlar-and-mekinist-receive-fda-priority-review-designation/2458904/The FDA has granted priority review for the same patient population for the combination of Novartis’ Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Also, the Committee for Medi
- Dermatologist Warns of "Lime Disease"—Phytophotodermatosis—In Conjunction with National Tequila Dayhttps://practicaldermatology.com/news/dermatologist-warns-of-lime-diseasephytophotodermatosisin-conjunction-with-national-tequila-day/2458907/Margaritas may be the choice cocktail on July 24 to celebrate National Tequila Day, but Dr. Howard Steinman, a dermatologist with DermOne Dermatology Centers, has a sour warning: Sipping citrus fruit
- ASDS Finds Age Affects Facial Treatment Preferenceshttps://practicaldermatology.com/news/asds-finds-age-affects-facial-treatment-preferences/2458908/A research-based analysis published in Dermatologic Surgery found that facial treatment preferences among women often are tied to their age. Younger women are more likely to seek cosmetic medical treatments for the upper face while women 50 and older prioritize treatments of the lower fa
- Brickell Biotech Appoints Patricia Walker, MD, PhD as President and CSOhttps://practicaldermatology.com/news/brickell-biotech-appoints-patricia-walker-md-phd-as-president-and-cso/2458912/Patricia Walker, MD, PhD has joined Brickell Biotech, Inc. as President and Chief Scientific Officer. Dr. Walker, a board-certified dermatologist specializing in medical and aesthetic dermatology, most recently served as the Chief Medical Officer for Kythera Biopharmaceuticals, Inc. Over